PLoS One by Smith, Rachel M. et al.
Prevalence of Cryptococcal Antigenemia and Cost-
Effectiveness of a Cryptococcal Antigen Screening
Program – Vietnam
Rachel M. Smith1,2*, Tuan Anh Nguyen3, Hoang Thi Thanh Ha3, Pham Hong Thang3, Cao Thuy4,
Truong Xuan Lien5, Hien T. Bui6, Thai Hung Le7, Bruce Struminger6, Michelle S. McConnell7, Robyn
Neblett Fanfair2, Benjamin J. Park2, Julie R. Harris2
1 Epidemic Intelligence Service, Scientific Education and Professional Development Program Office, Centers for Disease Control and Prevention, Atlanta, Georgia, United
States of America, 2 Division of Foodborne, Waterborne, and Environmental Diseases, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease
Control and Prevention, Atlanta, Georgia, United States of America, 3 National Institute for Hygiene and Epidemiology, Hanoi, Vietnam, 4 National Hospital of Tropical
Diseases, Hanoi, Vietnam, 5 Pasteur Institute, Ho Chi Minh City, Vietnam, 6 Division of Global HIV/AIDS, Centers for Disease Control and Prevention, Hanoi, Vietnam,
7 Division of Global HIV/AIDS, Centers for Disease Control and Prevention, Ho Chi Minh City, Vietnam
Abstract
Background: An estimated 120,000 HIV-associated cryptococcal meningitis (CM) cases occur each year in South and
Southeast Asia; early treatment may improve outcomes. The World Health Organization (WHO) recently recommended
screening HIV-infected adults with CD4,100 cells/mm3 for serum cryptococcal antigen (CrAg), a marker of early
cryptococcal infection, in areas of high CrAg prevalence. We evaluated CrAg prevalence and cost-effectiveness of this
screening strategy in HIV-infected adults in northern and southern Vietnam.
Methods: Serum samples were collected and stored during 2009–2012 in Hanoi and Ho Chi Minh City, Vietnam, from HIV-
infected, ART-naı̈ve patients presenting to care in 12 clinics. All specimens from patients with CD4,100 cells/mm3 were
tested using the CrAg lateral flow assay. We obtained cost estimates from laboratory staff, clinicians and hospital
administrators in Vietnam, and evaluated cost-effectiveness using WHO guidelines.
Results: Sera from 226 patients [104 (46%) from North Vietnam and 122 (54%) from the South] with CD4,100 cells/mm3
were available for CrAg testing. Median CD4 count was 40 (range 0–99) cells/mm3. Nine (4%; 95% CI 2–7%) specimens were
CrAg-positive. CrAg prevalence was higher in South Vietnam (6%; 95% CI 3–11%) than in North Vietnam (2%; 95% CI 0–6%)
(p = 0.18). Cost per life-year gained under a screening scenario was $190, $137, and $119 at CrAg prevalences of 2%, 4% and
6%, respectively.
Conclusion: CrAg prevalence was higher in southern compared with northern Vietnam; however, CrAg screening would be
considered cost-effective by WHO criteria in both regions. Public health officials in Vietnam should consider adding
cryptococcal screening to existing national guidelines for HIV/AIDS care.
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Introduction
Cryptococcal meningitis (CM) is one of the most common
opportunistic infections (OI) among HIV-infected individuals, with
an estimated 1 million cases of HIV-associated CM and 600,000
deaths each year [1]. Of those, an estimated 120,000 CM cases
and 66,000 deaths occur in South and Southeast Asia [1], making
CM one of the three most common HIV-associated OIs [2,3,4] in
this region. Despite access to appropriate antifungal treatment,
CM mortality in this region is between 40–55% [1,5,6],
considerably higher than CM mortality in the developed world
[1,7].
Reducing CM mortality has long been a focus of HIV care and
treatment programs; however, recently the focus has shifted from
improving CM treatment to preventing symptomatic CM through
early cryptococcal disease detection and pre-emptive treatment.
CM represents a disseminated form of cryptococcal disease that
requires hospitalization, with costly drug regimens (including
amphotericin B) that have substantial side effects. Although early
infection is treatable with relatively inexpensive and non-toxic
drugs (typically oral fluconazole), it may be asymptomatic and thus
go unnoticed. Cryptococcal antigen (CrAg), a biologic marker of
cryptococcal infection, is detectable in sera a median of 3 weeks
(range 5–234 days) before symptoms of meningitis appear [8], and
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is most commonly found in patients with CD4,100 cells/mm3
[9]. Otherwise healthy HIV-infected persons with detectable
serum CrAg have increased mortality when compared to their
CrAg-negative counterparts [10,11]; pre-emptive treatment of
serum CrAg-positive patients with fluconazole and anti-retroviral
therapy (ART) has been shown, in a small observational study, to
improve survival [12], compared with ART alone, and has been
recommended for consideration by the World Health Organiza-
tion (WHO) [13]. This period of asymptomatic antigenemia
before symptomatic meningitis provides a window of opportunity
to treat patients and potentially prevent fatal cryptococcal disease.
Use of CrAg detection tests in resource-limited regions has been
limited by the expense and laboratory infrastructure required.
However, the recent development of an inexpensive, easy-to-use,
highly sensitive and specific [14] dipstick CrAg detection test
called the lateral flow assay (LFA) (Immy, Norman, Oklahoma,
USA) may increase accessibility of CrAg testing for clinicians in
resource-limited settings. In 2011, the WHO released guidelines
for diagnosis, prevention and management of cryptococcal disease,
which recommended consideration of serum CrAg-based screen-
ing for early cryptococcal infection using antigen-based tests,
including the LFA [13]. The target population for screening is
HIV-infected persons with a CD4,100 cells/mm3 living in areas
with a high prevalence of cryptococcal disease [13]. However, the
circumstances under which CrAg screening programs are cost-
effective are country-specific, as they depend not only on
prevalence of cryptococcal disease, but also local drug costs and
other aspects of treatment. Existing data demonstrating the cost-
effectiveness of CrAg screening programs are limited to studies
from Uganda [12,15], where costs and CrAg prevalence differ
from those in Southeast Asia, and Cambodia [16], where a model
with inputs that differ substantially from the WHO-recommended
cryptococcal screening strategy was utilized.
To date, two small studies have evaluated the serum CrAg
prevalence among high-risk (CD4,100 cells/mm3) HIV-infected
patients in Southeast Asia: in Thailand, the observed prevalence
was 13% [9], and in Cambodia, 21% [17]. In Vietnam, situated
near both Cambodia and Thailand, between 200,000–350,000
persons were projected to be living with HIV/AIDS by 2012 [18].
Although a small number of studies have described the burden of
cryptococcal meningitis in Vietnam [2,19,20], the prevalence of
serum CrAg positivity among HIV-infected individuals is not
known. We evaluated the prevalence of serum CrAg in Vietnam
among HIV-infected persons with CD4,100 cells/mm3, and
modeled the cost-effectiveness of an in-country screening program.
Methods
Study Enrollment and Specimen Testing
The BED-assay study (an HIV incidence validation study which
used the BED-capture enzyme immunoassay to estimate time
since HIV infection [21]) and HIV-DR (HIV Drug Resistance)
monitoring study, both conducted in Vietnam, provided stored
serum samples for serum CrAg testing. The BED study was
conducted from April – December 2009 in Hanoi, Ho Chi Minh
City (HCMC), Haiphong, and Quang Ninh; eligible enrollees
were ART-naı̈ve adults ($18 years of age) with documented HIV
infection for at least one year [22] presenting to outpatient clinics
(OPCs) for HIV care. Patients from the BED study were excluded
from this sub-study if they had a recent or current diagnosis of
CM. The HIV-DR study began in November 2009, and is
scheduled for completion in March 2013. Enrollees were adults
($18 years of age) with HIV infection initiating a first-line ART
regimen at eight OPCs in northern and southern Vietnam. Sera
collected at study enrollment from patients with CD4,100 cells/
mm3 in both studies were stored at 220uC to 280uC at the
National Institute for Hygiene and Epidemiology (NIHE) in Hanoi
and Pasteur Institute (PI) in HCMC, and were retrieved for CrAg
LFA testing in this sub-study during 2012. Training of laboratory
staff to perform and interpret the LFA was completed before CrAg
testing at both sites. Institutional review board (IRB) approval for
this study was obtained from the IRB at the Centers for Disease
Control and Prevention and the Vietnam Ministry of Health.
Surviving patients from both the BED-assay and HIV-DR studies
gave written informed consent after sera collection to have their
remnant sera tested for CrAg in this sub-study. Deceased patients
were exempt from the informed consent process and their sera
were also tested for CrAg.
Specimen Data Analysis
All analysis was done in SAS 9.3 (SAS Institute Inc., Cary, NC,
USA). The x2 or Fisher’s exact tests (when cell sizes,5) were used
to compare proportions. The Wilcoxon rank-sum test was
performed for comparison of medians.
Definitions
For the cost-effectiveness model, CM is defined as a positive
lumbar puncture (LP) in any patient, regardless of symptoms. LP
positivity includes evidence of cryptococcosis in the cerebrospinal
fluid (CSF) by any method (antigen test, India Ink, or culture). A
positive symptom screen for CM is defined as one or more of the
following symptoms: fever, headache, blurry vision, confusion,
neck stiffness/soreness, or sensitivity to light. Isolated serum CrAg
positivity, or asymptomatic cryptococcal antigenemia, is defined as
a positive serum LFA result for CrAg in the absence of a positive
symptom screen or positive LP. LP refusal includes all patients
who do not have an LP performed after referral. We used WHO’s
Choosing Interventions that are Cost Effective (CHOICE)
guidelines [23,24] to evaluate cost-effectiveness.
Cost-effectiveness Evaluation and Assumptions
We evaluated the incremental cost-effectiveness of a CrAg
screening program among Vietnamese HIV-infected patients
newly presenting for ART at an OPC, and compared it to the
current standard of care for HIV-infected patients in Vietnam (no
cryptococcal screening, only treatment for symptomatic CM) [25].
General assumptions of this model include the following: 1) no
patient treated for isolated positive serum CrAg develops CM; 2)
loss to follow-up is negligible; and 3) the sensitivity and specificity
of the LFA are 100%. Outcomes evaluated included number
needed to screen to prevent one case of CM; number needed to
screen to prevent one CM death; and (undiscounted) cost per life-
year gained.
Model Flow
Figure 1 demonstrates the flow of patients through a model
cryptococcal screening program, adapted from the national
cryptococcal screening program in South Africa [26]. Based on
the model, ART-naı̈ve patients presenting to an OPC with
CD4,100 cells/mm3 receive serum CrAg testing; if negative,
patients are initiated on ART as per Vietnam national HIV
guidelines [25] and receive no further CrAg testing or treatment.
Serum CrAg-positive patients return for an additional clinic visit
and symptom screen. Patients with a negative symptom screen will
receive treatment for isolated serum CrAg positivity (oral
fluconazole, per WHO recommendations [13]). Patients with a
positive symptom screen are referred for LP at a designated
Cryptococcal Screening in Vietnam
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hospital. If the LP is positive, the patient will be treated for CM
according to current Vietnamese national HIV guidelines [25]. If
the LP is negative, the patient will be treated for isolated serum
CrAg positivity with oral fluconazole [13]. If a symptomatic
patient refuses LP, he/she will be referred for empiric CM
treatment (Figure 1).
Costs
All costs and assumptions are included in Tables 1 and 2. The
LFA cost was derived from the manufacturer’s recommended
retail price for resource-limited settings [27]. Per-unit costs for
fluconazole and amphotericin B were provided by the HCMC
People’s Action Committee (PAC), the administrative body that
oversees delivery of HIV/AIDS care in HCMC. CM treatment
was based on current Vietnamese national HIV guidelines [25],
and includes a 14-day course of amphotericin B followed by
fluconazole until immune reconstitution. Treatment of isolated
serum CrAg positivity was based on the WHO guidelines for
diagnosis, prevention and management of cryptococcal disease,
and includes one year of fluconazole: 800 mg/day for two weeks,
followed by 400 mg/day for eight weeks, followed by 200 mg/day
maintenance [13]. Clinical cost estimates, including the cost of
clinic visits, personnel time, diagnostic tests (e.g. LP, culture),
hospitalization, and follow-up were provided by the National
Hospital for Tropical Diseases (NHTD) in Hanoi (Dr. Cao Thuy,
personal communication). These costs were compared with those
at the Tropical Disease Hospital in HCMC and found to be
equivalent. All direct costs, including physician care, hospitaliza-
tion, and nursing care, were incorporated into the model. Indirect
costs were not included in this analysis. Costs of CD4 testing, the
initial clinic visit for enrollment in HIV care, and subsequent cost
of ART are not included, as those do not represent additional costs
to the system. Costs were not discounted in this model as they
accrued over less than a one-year time horizon.
Assumptions under Non-screening Scenario
Table 2 outlines assumptions used in the cost-effectiveness
model. Six-month mortality estimates among CM patients in a
non-screening situation (i.e., current standard of care) were based
on reports from existing literature [5,6]. Six-month mortality
among non-CM patients in a non-screening scenario was assumed
to be 10%, slightly higher than mortality among serum CrAg-
negative patients reported in a previous study (under a screening
scenario) [10]. The proportion of unscreened patients who
progress to meningitis was derived from existing literature [11].
Figure 1. Cryptococcal screening algorithm. This algorithm, adapted from the South African national cryptococcal screening program, shows
the flow of evaluation of HIV-infected patients in a model cryptococcal screening program. First, all patients with CD4,100 cells/mm3 undergo
cryptococcal antigen (CrAg) testing. Those patients with a positive CrAg test then return to clinic for a symptom screening, followed by lumbar
puncture referral for patients with a positive symptom screen. The algorithm also outlines the appropriate treatment for different patients within the
screening program. Patients who have a negative CrAg test do not receive fluconazole but instead initiate antiretroviral therapy (ART) as per usual
clinic practice. Patients who have a positive CrAg test and have a negative symptom screen or who have a positive symptom screen but negative
lumbar puncture are treated with oral fluconazole for prevention of cryptococcal meningitis. Patients who have a positive symptoms screen and
positive lumbar puncture are treated for cryptococcal meningitis according to Vietnam’s national HIV guidelines, with amphotericin B followed by
fluconazole. Persons who have a positive symptom screen but refuse lumbar puncture are treated presumptively for cryptococcal meningitis. All
CrAg-positive patients are initiated on ART after a minimum of two weeks of cryptococcal treatment (either for asymptomatic antigenemia,
diagnosed, or presumptive cryptococcal meningitis).
doi:10.1371/journal.pone.0062213.g001
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Table 1. Costs associated with cryptococcal meningitis diagnosis, treatment and a cryptococcal screening program in Vietnam, in
US dollars.
Item Unit Cost # Units/Days Total Cost
Costs for all screened patients
LFA test $4.13 1 $4.13
Additional costs for all serum CrAg-positive patients
Return clinic visit for symptom screen $5.00 1 $5.00
Additional costs for symptom screen positive patients
Lumbar puncture $1.68 1 $1.68
Testing on CSF* $21.62 1 $21.62
Additional costs for LP positive/Cost to treat Cryptococcal Meningitis
Lumbar puncture $1.68 5 $8.40
Testing on CSF* $21.62 2 $43.24
Hospitalization in ICU $16.80 7 $117.60
Hospitalization in ward bed $2.40 13 $31.20
Laboratory costs $4.81 10 $48.10
Care services in ICU $8.75 7 $61.25
Amphotericin IV $8.17 14 $114.38
Fluconazole 800 mg/day $2.31 56 $129.36
Fluconazole 200 mg/day $0.58 295 $170.10
Additional costs for serum CrAg-positive, LP-negative patients
Fluconazole 800 mg/day $2.31 14 $32.34
Fluconazole 400 mg/day $1.17 56 $64.52
Fluconazole 200 mg/day $0.58 295 $170.10
*Inclusive of: CSF culture, cell count, glucose, protein, India Ink, and LFA.
doi:10.1371/journal.pone.0062213.t001
Table 2. Assumptions of a cost-effectiveness model for cryptococcal screening in Vietnam.
Assumption Value Source
General
Average age of CM diagnosis 28 [29]
Years of life gained if a person does not die of CM 25 [30,31]
% of antigenemic patients who get CM if no antifungal treatment 30% [11]
Screening
% of patients with a positive symptom screen 50% Personal communication*
% of patients who refuse an LP 5% Personal communication*
% of positive LPs among serum CrAg-positive patients 50% [9,28]
Six-month mortality among isolated serum CrAg-positive patients 15% [12,17]
Six-month mortality among CM patients 30% [5,6]**
Six-month mortality among serum CrAg-negative patients 5% [10]
Six-month mortality among LP refusers 20% Extrapolated
No Screening
Six-month mortality among CM patients 45% [5,6]
Six-month mortality among non-CM patients 10% [10]***
*Dr. Cao Thuy, physician.
**Assumed to be slightly lower than mortality among CM patients under existing standard of care, due to earlier diagnosis and treatment.
***Assumed to be slightly higher than mortality among serum CrAg-negative patients under a screening scenario.
doi:10.1371/journal.pone.0062213.t002
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Assumptions under Screening Scenario
With screening, six-month CM mortality among patients
diagnosed with cryptococcal meningitis was assumed to be slightly
lower (due to presumed diagnosis and treatment of disease at an
earlier stage) than CM mortality under the non-screening scenario
(Table 2). Currently, no data are available regarding mortality
among isolated serum CrAg-positive patients treated with a
standardized, WHO-recommended fluconazole regimen, so we
assumed their mortality to be slightly lower than reported rates of
mortality in serum CrAg-positive patients, all of whom were
treated with a non-standardized regimen [12,17]. Six-month
mortality among serum CrAg-negative patients was derived from a
previous study [10]. Six-month mortality among serum CrAg-
positive patients who refuse LP was assumed to be a value
intermediate between the estimated mortality in isolated serum
CrAg-positive and CM patients.
The estimated proportion of serum CrAg-positive patients with
a positive LP after a symptom screen was based on reports in the
literature [9,28]. The proportion of patients with a positive
symptom screen and the frequency of LP refusals were estimated
through consultation with in-country physicians with experience in
HIV care, including care for persons with CM (Dr. Cao Thuy,
personal communication) Average age at diagnosis of CM was
derived from the literature [29], as was life expectancy of HIV-
infected persons on ART with CD4,100 cells/mm3 [30,31].
Data Analysis: Cost-effectiveness Model
The number of patients needed to screen (NNS) to prevent one
case of CM or one death from CM was calculated as:
NNS~Total #of patients undergoing screening=
#of CM cases (or deaths) without screening½ 
{ #of CM cases (or deaths) with screening½ 
 !
Undiscounted life-years gained (LYG) were calculated by
multiplying excess deaths from CM by years of life gained when
a screened patient did not die from CM. We calculated the
incremental cost effectiveness ratio (ICER) of screening as the
excess cost associated with screening divided by the number of
LYG through screening.
Alternate Models: Cost and Length of Fluconazole
Treatment
Currently, WHO-recommended length of fluconazole mainte-
nance treatment for isolated serum CrAg-positive patients (until
immune reconstitution) is based on expert opinion. In our model,
we assumed the total time required for treatment of an isolated
serum CrAg-positive patient was one year of fluconazole therapy.
However, at least one observational study has demonstrated a
survival benefit with as few as 2–4 weeks of fluconazole therapy
[12]; other clinicians have suggested that fluconazole treatment
past 10 weeks may be unnecessary [15]. Due to this uncertainty,
fluconazole treatment lengths of 10 weeks and 1 year were both
evaluated in this analysis under the same presumed effectiveness in
preventing CM. In addition, because some countries, including
Vietnam, receive no-cost fluconazole for CM treatment through
Pfizer’s Diflucan Partnership Program (DPP) [32], we calculated
cost per LYG for full-cost (at 10 weeks and 1 year of treatment)
and no-cost fluconazole. All cost-effectiveness modeling was done
in MS Excel 2010 (Microsoft Corp., Redmond, WA, USA).
Sensitivity Analysis
To evaluate the sensitivity of the model, we calculated cost per
LYG while varying CrAg prevalences (2%, 4%, and 6%), LFA test
costs (+/250%), fluconazole costs (+/250%), percentage of serum
CrAg-positive patients with a positive symptom screen (+/220%),
percentage of patients with a positive LP (+/220%), six-month
mortality rate among screened patients with CM (+/250%), and
with discounting of health benefits at 3% and 5%.
Results
Serum CrAg Prevalence Overall, and by Region
Two hundred twenty-six patients with CD4,100 cells/mm3
were evaluated for serum CrAg: 142 from the BED study and 84
from the HIV-DR study. Median CD4 count was 40 (range: 0–99)
cells/mm3, and was significantly lower in the South compared
with the North (28 vs. 51 cells/mm3, p,0.0001). Nine (4%; 95%
CI 2–7%) serum CrAg-positive samples were identified; two (2%,
95% CI 0–6%) of 104 specimens from patients in North Vietnam
and seven (6%, 95% CI 3–11%) of 122 specimens from patients in
South Vietnam (p = .18). Median CD4 count was not different
between CrAg-positive and CrAg-negative persons (39 vs. 40
cells/mm3, p = 0.86). Five (56%) of the nine CrAg-positive tests
occurred in persons with a CD4,50 cells/mm3 (Table 3). No
patient enrolled in the BED study had a recent or current
diagnosis of CM at the time of enrollment; these data were not
available for patients from the HIV-DR study.
Cost-effectiveness of Screening
With a full year of fluconazole treatment for isolated serum
CrAg-positive patients, the ICER for CrAg screening at a serum
CrAg prevalence of 4% is estimated at $137/LYG; at a prevalence
of 2% it is $190/LYG and at a prevalence of 6% is it $119/LYG.
For a limited 10-week course of fluconazole, the estimated ICER
of screening was $68/LYG at a serum CrAg-positive prevalence of
4%, $121/LYG at 2%, and $51/LYG at 6%. When fluconazole
costs are removed from the model (i.e., no-cost fluconazole), the
estimated ICER of screening is $43/LYG at a serum CrAg-
positive prevalence of 4%, $95/LYG at 2%, and $25/LYG at 6%.
Figure 2 shows the ICER at varying serum CrAg prevalences and
under different cost and fluconazole treatment length scenarios.
WHO considers an intervention to be ‘very cost-effective’ if the
ICER is less than the gross domestic product (GDP) per capita of
the WHO region (for Vietnam, $6,948) [23,24].
At a serum CrAg-positive prevalence of 4%, 228 patients with
CD4,100 cells/mm3 need to be screened to prevent one case of
CM, and 321 need to be screened to prevent one death from CM.
These values vary with the prevalence of cryptococcal disease
(Table 4).
Table 3. CrAg-positive prevalence by CD4 count and region
of Vietnam.
CD4 count
(cells/mm3) North South Total
50–99 1/53 (2%) 3/33 (9%) 4/86 (5%)
,50 1/51 (2%) 4/89 (4%) 5/140 (4%)
Total 2/104 (2%) 7/122 (6%) 9/226 (4%)
doi:10.1371/journal.pone.0062213.t003
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Sensitivity Analysis
The cost-effectiveness of screening for CrAg is inversely related
to LFA costs, fluconazole costs, the six-month CM mortality rate
among screened patients, the proportion of serum CrAg-positive
patients with a positive symptom screen, the proportion of patients
with a positive LP, and the discount rate of health benefits
(Table 5). The cost-effectiveness of screening was sensitive to
changes in six-month CM mortality among screened patients and
the discount rate of health benefits, but relatively insensitive to
changes in price of fluconazole, LFA cost, proportion of serum
CrAg-positive patients with a positive symptom screen and
proportion of patients with a positive LP (Table 5).
Discussion
Treatment of patients with HIV-associated CM is extremely
costly and is associated with poor outcomes in resource-limited
settings, such as Vietnam. Even under optimal circumstances,
mortality can be as high as 15% [7]. To reduce CM deaths, the
WHO has recommended consideration of screening HIV-infected,
ART-naı̈ve patients with CD4,100 cells/mm3 for cryptococcal
disease in areas with a high prevalence of Cryptococcus infection
[13]. In this analysis, we found serum CrAg to be present in 2–6%
of HIV-infected patients with CD4,100 cells/mm3 in Vietnam.
At these prevalences, a cryptococcal screening program in
Vietnam would cost less than $190 per life-year gained.
The lower prevalence of serum CrAg positivity we observed in
Vietnam, compared to neighboring countries, [9,17] might be due
to differences in the study populations. In Cambodia, serum CrAg
Figure 2. Cost-effectiveness of cryptococcal screening at a range of prevalences and cost scenarios. This graph has prevalence of
asymptomatic cryptococcal antigenemia on the x-axis and incremental cost-effectiveness ratio (ICER) (increased cost per life-year gained [LYG] in US
dollars) on the y-axis. The blue line represents the cost curve of full-cost fluconazole for one year of treatment. The red line represents the cost curve
of full-cost fluconazole for ten weeks of treatment; the green line represents the cost curve of if fluconazole is obtained at no-cost. For Vietnam, the
World Health Organization considers any intervention with an ICER under $6,948 to be ‘highly cost-effective’. This graph shows that cryptococcal
screening, at any prevalence and under each of the three cost scenarios, should be considered a highly cost-effective intervention in Vietnam.
doi:10.1371/journal.pone.0062213.g002
Table 4. Number Needed to Screen (NNS), by prevalence of serum CrAg-positive persons in Vietnam.
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prevalence among persons with CD4,100 cells/mm3 was 21%
[17]; however, the population tested was 50% inpatients and most
already had symptomatic CM [17]. CrAg screening, as suggested
by the WHO, is intended to target HIV-infected persons with
CD4,100 cells/mm3 who are healthy enough to present for
initiation of ART. Our prevalence estimates are closer to those
found among HIV-infected patients presenting for ART initiation
at ambulatory care clinics in sub-Saharan Africa (6% in Uganda
and 7% in Kenya) [10,33]. However, one study in Thailand which
evaluated asymptomatic, ART-naı̈ve patients found a CrAg-
prevalence of 13% [9], suggesting that there may be real
differences in prevalence of cryptococcal disease between regions
in Southeast Asia, perhaps due to environmental or host factors. It
is worth noting that all currently available estimates of CrAg
prevalence in Southeast Asia are based on small samples of
patients; data from larger studies would provide more robust
estimates with which to compare regional differences. The lower
prevalence of serum CrAg positivity in northern versus southern
Vietnam, while not statistically significant and based on small
patient numbers, is consistent with published findings from studies
of OIs in major referral hospitals in Hanoi [34] and HCMC [2,29]
which documented less CM in the north than the south of
Vietnam.
Interest in primary cryptococcal prophylaxis with an oral azole
for all high-risk patients, though initially supported by the WHO
[35], has declined in recent years due to the expense, concerns
about resistance, and the failure to consistently document a
survival benefit [36,37,38,39,40]; targeted screening was consid-
ered likely to be a more cost-effective approach. Several articles
have been published on cryptococcal screening in recent years
[10,11,12,15,16,17,26,33,41,42], resulting in increased country-
level interest in implementation of CrAg screening programs.
South Africa, with the largest population of HIV-infected persons
in the world, began a nationwide rollout of cryptococcal screening
at outpatient clinics in mid-2012, integrating screening into their
national health plan [26]. Given the increasing interest in CrAg
screening in resource-limited settings, a detailed cost-effectiveness
evaluation, such as the one presented here, is essential for program
planning, appropriate budgeting and allocation of limited
resources, and subsequent program monitoring and evaluation.
We chose cost/LYG as our metric of evaluation in this paper for
several reasons. First, although data on CM mortality in resource-
limited settings are already fairly well-established [1], disability due
to CM is poorly quantitated in these same areas, making metrics
such as DALYs or QALYs potentially less valid and less
meaningful than LYG, which includes only effects on mortality.
Additionally, cost/LYG is a relatively easy and transparent
method for measuring population health for a disease with high
mortality, such as CM, and is easily comparable across interven-
tions. Using cost/LYG, we found that the incremental cost-
effectiveness of cryptococcal screening in Vietnam varied widely,
from $4–296/LYG, based on serum CrAg prevalence and
inclusion of fluconazole costs (Figure 2). WHO-CHOICE
guidelines consider a very cost-effective intervention to be one in
which the incremental cost-effectiveness ratio is less than the GDP
per capita in the respective WHO region [23]. Vietnam is in the
West Pacific Region (WPRO) B region which has an estimated
GDP per capita of $6,948 [24], making the implementation of a
cryptococcal screening program very cost-effective, by WHO
standards, at all CrAg prevalence estimates evaluated in this study.
In 2011, the World Bank estimate of per capita GDP in Vietnam
was $1,411 [43]; while significantly lower than the WPRO B per
capita GDP, it is still within a range in which a cryptococcal
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WHO. In addition, cryptococcal screening compares favorably to
other HIV care interventions: cost-effectiveness studies of
cotrimoxazole prophylaxis show a cost/LYG of $150–$1180
[44], while studies of ART report a cost/LYG of $430 to
.$1,000 [45,46,47].
It is worth noting that previous evaluations of cost-effectiveness
of CrAg screening either have not included fluconazole costs [12]
or have included a much-reduced regimen, in both dosage and
length of treatment, compared with the WHO-recommended
regimen [16]. Fluconazole maintenance therapy for isolated serum
CrAg-positive patients, as recommended in the WHO guidelines,
comprises a substantial proportion of the cost of a screening
program, due to the recommendation to treat until immune
reconstitution (assumed to be 1 year of treatment in this analysis).
While inclusion of the WHO-recommended fluconazole regimen
does not make cryptococcal screening cost-ineffective in our
analysis, it does increase costs substantially, which warrants
consideration in the implementation planning of this and other
large-scale cryptococcal screening programs. Our values for the
NNS to avoid one case and one death from CM are slightly higher
than other estimates in the literature [11,12], likely due to
differences in the CrAg prevalence between Vietnam and sub-
Saharan Africa, where other studies reporting NNS were
conducted.
This study includes the following limitations. First, all costs and
most assumptions were based on data from Vietnam or Southeast
Asia, and may not be generalizable to other regions of the world.
Our estimates of CrAg prevalence are based on a limited number
of patients accessing care at clinics in two regions of Vietnam, and
may not be generalizable to the entire country; larger studies of
HIV-infected persons in multiple regions of Vietnam should be
undertaken to better understand the country-wide burden of
cryptococcal disease. Second, the flow and management of
patients through our screening model represent ideal practice;
real-world practices may be different. Third, we lacked clinical
data for participants from the HIV-DR study and were thus
unable to rule out current or recent CM in those patients. Finally,
most of the assumptions underpinning this model were derived
from small observational studies, including data on the mortality
benefit from early treatment of CrAg-positive persons with
fluconazole. Further research, including randomized controlled
trials of fluconazole for early cryptococcal disease, is needed to
confirm these preliminary data.
To the best of our knowledge, this is the first study to estimate
the prevalence of serum CrAg positivity in Vietnam. It is also the
first evaluation of the cost-effectiveness of cryptococcal screening
according to treatment outlined in the WHO guidelines for
diagnosis, prevention and management of cryptococcal disease.
Based on our estimates of CrAg prevalence in Vietnam,
implementation of a cryptococcal screening program is both
indicated and highly cost-effective in Vietnam.
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